Literature DB >> 8949451

Raynaud's phenomenon and digital necrosis induced by interferon-alpha.

C Bachmeyer1, D Farge, E Gluckman, J M Miclea, S Aractingi.   

Abstract

We report two patients treated with interferon-alpha who developed Raynaud's phenomenon followed by multiple digital necrosis. Arteriography of the legs revealed diffuse distal narrowing. Histological examination of the resected tissue showed ischaemic necrosis within the dermis and subcutaneous tissue without vasculitis. Resolution of the symptoms was observed when interferon-alpha was withdrawn. Since other causes of Raynaud's phenomenon and digital necrosis were ruled out, a drug cause is likely. Raynaud's phenomenon should be looked for in patients treated with interferon-alpha. If present, immediate withdrawal of the drug is required.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8949451

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


  5 in total

1.  Aicardi-Goutières syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21.

Authors:  Y J Crow; A P Jackson; E Roberts; E van Beusekom; P Barth; P Corry; C D Ferrie; B C Hamel; R Jayatunga; G Karbani; R Kálmánchey; A Kelemen; M King; R Kumar; J Livingstone; R Massey; R McWilliam; A Meager; C Rittey; J B Stephenson; J L Tolmie; A Verrips; T Voit; H van Bokhoven; H G Brunner; C G Woods
Journal:  Am J Hum Genet       Date:  2000-05-25       Impact factor: 11.025

2.  Digital ischemic necrosis caused by pegylated interferon in a patient with hepatitis C.

Authors:  Jana G Hashash; Sean A Tackett; David J McAdams
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-02-06

Review 3.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

4.  Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutières Syndrome Treated With Ruxolitinib.

Authors:  Abirami Pararajasingam; Rachel E Bradley; Jennifer Evans; Ashima Lowe; Richard Goodwin; Stephen Jolles
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

5.  Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

Authors:  Jo N Fleming; Richard A Nash; D O McLeod; David F Fiorentino; Howard M Shulman; M Kari Connolly; Jerry A Molitor; Gretchen Henstorf; Robert Lafyatis; David K Pritchard; Lawrence D Adams; Daniel E Furst; Stephen M Schwartz
Journal:  PLoS One       Date:  2008-01-16       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.